Public Health Agency of Canada
Symbol of the Government of Canada

Share this page

Canada Communicable Disease Report CCDR

ISSN 1481-8531 (On-line)


CCDR: Volume 40-2, January 24, 2014

For readers interested in the PDF version, the document is available for download or viewing: CCDR: Volume 40-2, January 24, 2014 (PDF document - 420 KB - 13 pages)


Notes from the Editor

A new virus in the Caribbean

Most people in Canada have never heard of chikungunya. Until recently it was one of those obscure vector-borne diseases found largely in Asia and Africa. But now it is a little closer to home. In December 2013, an outbreak of this dengue-like illness was identified in several Caribbean countries. And how many Canadians go to the Caribbean in the winter-time? Suddenly it is very possible that we will see chikungunya in Canada. It is not a nice disease; and it can linger. In this issue we have an Early Communication article on what you need to know to prevent, detect and manage it. Also in this issue, we offer some insights into how vaccine recommendations are made in Canada through two summaries of statements from the Canadian Immunization Committee.

Early Communications

Chikungunya virus in the Caribbean (2013-2014). Deilgat M, Geduld J, Drebot M.

Recommendations to manage chikungunya virus, include preventing mosquito bites, early diagnosis, laboratory testing and reporting to public health authorities.

Summaries

Recommendations for Rotavirus Immunization Programs - Canadian Immunization Committee

The CIC supports the routine use of rotavirus vaccines in infants without contraindications based on the recommendations of the National Advisory Committee on Immunization, Canadian studies that demonstrate its cost-effectiveness and evidence of high acceptability and feasibility.

Recommendations for Varicella Two-dose Immunization Programs - Canadian Immunization Committee

The CIC supports the routine use of a 2-dose varicella vaccine schedule on a voluntary basis based on the recommendations of NACI, initial evidence for cost-effectiveness, and anticipated acceptability.

What's new

Emerg Inf Dis Feb 2014 Investigation of Inhalation anthrax case, United StatesExternal Link. Griffith J, Blaney D, Shadomy S, Lehman M, Pesik N, Tostenson S, Delaney L, Tiller R, DeVries A, Gomez T, Sullivan M, Blackmore C, Stanek D, Lynfield R, and the Anthrax Investigation Team.

A 61 year old man developed anthrax likely due to inhalation of spore-contaminated soil after travelling through 4 states in the US. (pre-print)

Eurosurv Jan 2014 Conclusions of the fourth CONSISE international meetingExternal Link. Van Kerkhove M, Wood J, on behalf of CONSISE.

The Consortium for Standardization of Influenza SeroepidemiologyExternal Link has developed study protocol templates to evaluate the seroprevalence of seasonal, pandemic and zoonotic influenza viruses in specific human populations and standardised the international serology laboratory response to a new emerging influenza virus.

Useful links

Rotavirus vaccine National Advisory Committee on Immunization. Canadian Immunization Guide Part 4. 2012

Recommendations for Rotavirus Immunization ProgramsExternal Link

Varicella vaccine National Advisory Committee on Immunization. Canadian Immunization Guide Part 4. 2012

Recommendations for Varicella Two-Dose Immunization ProgramsExternal Link